Results 21 to 30 of about 17,963 (297)
Update in Pathogenesis, Diagnosis, and Therapy of Prolactinoma
Cancers, 2022 Simple Summary This review updates recent advances in the pathogenesis, diagnosis, and therapy of prolactinoma. Prolactinomas, comprising 30–50% of all pituitary neuroendocrine tumors, frequently occur in females aged 20 to 50 and cause hypogonadism and ...
Noriaki Fukuhara +2 more
semanticscholar +1 more source
Endocrine Oncology, 2022 The current treatment paradigm for prolactinomas involves dopamine agonist (DA) therapy as the first-line treatment, with surgical resection reserved for cases where there is DA failure due to resistance or intolerance.
S. M. D. De Sousa
semanticscholar +1 more source
Arquivos Brasileiros de Endocrinologia & Metabologia, 2014 Os prolactinomas são os adenomas de hipófise mais comuns e frequentemente afetam mulheres jovens, em faixa etária de fertilidade. A hiperprolactinemia causa hipogonadismo, irregularidade menstrual ou amenorreia em mulheres, níveis baixos de testosterona sérica em homens e infertilidade e disfunção sexual em ambos os gêneros.
Glezer, Andrea, Bronstein, Marcello D.
openaire +4 more sources
The Effect of Prolactinoma on Tear Film Function
Türk Oftalmoloji Dergisi, 2022 Objectives:To compare dry eye parameters in prolactinoma patients and healthy controls and evaluate their correlation with prolactin (PRL) levels and the duration of hyperprolactinemia.Materials and Methods:Consecutive patients with prolactinoma and ...
Cezmi Doğan +5 more
doaj +1 more source
Prolactinoma: Clinical Characteristics, Management and Outcome
Cureus, 2022 Aim Prolactinoma, a prolactin (PRL) secreting functioning pituitary tumor, is the most common of all pituitary adenomas (PA) accounting for 40-60% and dopamine agonists (DA) are the cornerstone of treatment.
Hira Irfan +8 more
semanticscholar +1 more source
Journal of Clinical Endocrinology and Metabolism, 2022 CONTEXT Dopamine agonist-induced (DA-induced) impulse control disorder (ICD) represents a group of behavioral disorders that are increasingly recognized in patients with prolactinoma.
S. Şahin +8 more
semanticscholar +1 more source
Treatment of patients with prolactinomas [PDF]
Obstetrical & Gynecological Survey, 1978 Fifty-one female patients with prolactin producing tumors (PRL 1100 to 88,000 microU/ml) and 26 male patients with prolactin producing tumors (PRL 6500 to 400,000 microU/ml) were studied. Only 25% of the females had visual field defects which were present in 70% of the males. All females had amenorrhea but only 35 had galactorrhea.
Fahlbusch, R. +5 more
core +7 more sources
The SF3B1R625H mutation promotes prolactinoma tumor progression through aberrant splicing of DLG1
Journal of experimental & clinical cancer research : CR, 2021 Recently, a hotspot mutation in prolactinoma was observed in splicing factor 3b subunit 1 (SF3B1R625H), but its functional effects and underlying molecular mechanisms remain largely unexplored.
Jing Guo +7 more
semanticscholar +1 more source
Scientific Reports, 2021 Prolactinomas represent the most common type of secretory pituitary neoplasms, with a therapeutic management that varies considerably based on tumour size and degree of hyperprolactinemia.
Bianca M. Leca +7 more
semanticscholar +1 more source
Cure and Hormonal Control After Prolactinoma Resection: Case Series and Systematic Review
Journal of the Endocrine Society, 2021 Context Surgical management of prolactinomas is an important treatment for patients intolerant of dopamine agonist therapy. However, predictors of postoperative outcomes remain unclear.
Marisa C Penn +10 more
semanticscholar +1 more source